Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Apollon Wealth Management LLC

Apollon Wealth Management LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 111.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,027 shares of the biopharmaceutical company’s stock after purchasing an additional 18,444 shares during the quarter. Apollon Wealth Management LLC’s holdings in Gilead Sciences were worth $2,838,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in GILD. Altfest L J & Co. Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter worth $210,000. Federated Hermes Inc. increased its holdings in shares of Gilead Sciences by 4.9% during the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after buying an additional 175,925 shares during the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $74,000. Abundance Wealth Counselors acquired a new position in Gilead Sciences in the third quarter valued at approximately $1,881,000. Finally, HTLF Bank purchased a new position in Gilead Sciences in the fourth quarter worth approximately $253,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 0.1 %

Shares of GILD traded down $0.08 during midday trading on Tuesday, reaching $65.46. The stock had a trading volume of 7,317,910 shares, compared to its average volume of 7,455,094. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The company’s fifty day simple moving average is $70.40 and its two-hundred day simple moving average is $75.68. The company has a market cap of $81.50 billion, a price-to-earnings ratio of 181.83, a PEG ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 1-year low of $64.33 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the previous year, the business earned $1.37 EPS. Gilead Sciences’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities research analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.71%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Maxim Group dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Barclays decreased their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Finally, TD Cowen lowered their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus price target of $83.69.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.